174 related articles for article (PubMed ID: 38365707)
1. Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion.
Zeng H; Zhang Y; Tan S; Huang Q; Pu X; Tian P; Li Y
BMC Pulm Med; 2024 Feb; 24(1):89. PubMed ID: 38365707
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14).
Boshuizen RC; Vd Noort V; Burgers JA; Herder GJM; Hashemi SMS; Hiltermann TJN; Kunst PW; Stigt JA; van den Heuvel MM
Lung Cancer; 2017 Jun; 108():9-14. PubMed ID: 28625655
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
[TBL] [Abstract][Full Text] [Related]
5. Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions.
Wang M; Sparrow K; Chan C; Gillson A; Stollery D; Li P
Respir Med; 2023 Jan; 206():107093. PubMed ID: 36549515
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Massarelli E; Onn A; Marom EM; Alden CM; Liu DD; Tran HT; Mino B; Wistuba II; Faiz SA; Bashoura L; Eapen GA; Morice RC; Jack Lee J; Hong WK; Herbst RS; Jimenez CA
Clin Lung Cancer; 2014 Sep; 15(5):379-86. PubMed ID: 24913066
[TBL] [Abstract][Full Text] [Related]
8. The Hospital and Patient Burden of Indwelling Pleural Catheters: A Retrospective Case Series of 210 Indwelling Pleural Catheter Insertions.
Asciak R; Hallifax RJ; Mercer RM; Hassan M; Wigston C; Wrightson JM; Psallidas I; Rahman NM
Respiration; 2019; 97(1):70-77. PubMed ID: 30227409
[TBL] [Abstract][Full Text] [Related]
9. [Complications after Indwelling Pleural Catheter Implant for Symptomatic Recurrent Benign and Malignant Pleural Effusions].
Langner S; Koschel D; Kleymann J; Tausche K; Karl S; Frenzen F; Heberling M; Schulte-Hubbert B; Halank M; Kolditz M
Pneumologie; 2020 Dec; 74(12):864-870. PubMed ID: 32663890
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
Nie K; Zhang Z; You Y; Zhuang X; Zhang C; Ji Y
Thorac Cancer; 2020 Jan; 11(1):8-14. PubMed ID: 31726490
[TBL] [Abstract][Full Text] [Related]
12. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
14. Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion.
Fitzgerald DB; Sidhu C; Budgeon C; Tan AL; Read CA; Kwan BCH; Smith NA; Fysh ET; Muruganandan S; Saghaie T; Shrestha R; Badiei A; Nguyen P; Burke A; Goddard J; Windsor M; McDonald J; Wright G; Czarnecka K; Sivakumar P; Yasufuku K; Feller-Kopman DJ; Maskell NA; Murray K; Lee YCG
Trials; 2022 Jun; 23(1):530. PubMed ID: 35761341
[TBL] [Abstract][Full Text] [Related]
15. Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis.
Yeung M; Loh EW; Tiong TY; Tam KW
Clin Exp Metastasis; 2020 Aug; 37(4):541-549. PubMed ID: 32524317
[TBL] [Abstract][Full Text] [Related]
16. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
Thomas R; Fysh ETH; Smith NA; Lee P; Kwan BCH; Yap E; Horwood FC; Piccolo F; Lam DCL; Garske LA; Shrestha R; Kosky C; Read CA; Murray K; Lee YCG
JAMA; 2017 Nov; 318(19):1903-1912. PubMed ID: 29164255
[TBL] [Abstract][Full Text] [Related]
17. [Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition)].
Chinese Thoracic Society, Chinese Medical Association
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Dec; 46(12):1189-1203. PubMed ID: 38044047
[TBL] [Abstract][Full Text] [Related]
18. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion.
Di W; Yue C; Ziran Z; Jie Z; Jun N; Ling D; Weiheng H; Xiaoling C; Xiangjuan M; Guangming T; Jindi H; Sen H; Yang W; Jieran L; Jian F
Future Oncol; 2022 Feb; 18(6):669-677. PubMed ID: 35080187
[No Abstract] [Full Text] [Related]
20. Silver Nitrate-coated versus Standard Indwelling Pleural Catheter for Malignant Effusions: The SWIFT Randomized Trial.
Shrager JB; Bhatnagar R; Kearney CT; Retzlaff NP; Cohen E; Stanton AE; Keyes C; Wahidi MM; Gillespie C; Rahman N; Kerry AL; Feller-Kopman D; Nader D; Akulian J; Chen A; Berry M; Majid A; Reddy C; Tremblay A; Maskell NA
Ann Am Thorac Soc; 2022 Oct; 19(10):1722-1729. PubMed ID: 35363591
[No Abstract] [Full Text] [Related]
[Next] [New Search]
